Biotech Values

[DewDiligence]

CNCE -3% despite FDA’s lifting on clinical hold:

https://finance.yahoo.com/news/fda-lifts-clinical-hold-concert-113000772.html

Concert Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has lifted the clinical hold on Concert’s CTP-543 Phase 2a clinical trial for alopecia areata.

The Company will amend the protocol for the Phase 2a trial to evaluate two doses of CTP-543, each for a 24 week duration. Concert will resume enrollment in the Phase 2a trial later this month and expects to complete the trial in the second half of 2018.